Charles Schwab Investment Management Inc. grew its holdings in Masimo Co. (NASDAQ:MASI - Free Report) by 2.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 377,836 shares of the medical equipment provider's stock after purchasing an additional 7,808 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.71% of Masimo worth $62,456,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently made changes to their positions in MASI. FMR LLC lifted its stake in shares of Masimo by 41.2% in the third quarter. FMR LLC now owns 6,756,618 shares of the medical equipment provider's stock valued at $900,860,000 after buying an additional 1,970,883 shares during the period. State Street Corp lifted its stake in shares of Masimo by 0.7% in the third quarter. State Street Corp now owns 1,438,814 shares of the medical equipment provider's stock valued at $191,837,000 after buying an additional 10,179 shares during the period. Westfield Capital Management Co. LP lifted its stake in shares of Masimo by 23.2% in the third quarter. Westfield Capital Management Co. LP now owns 1,394,056 shares of the medical equipment provider's stock valued at $185,869,000 after buying an additional 262,370 shares during the period. Geode Capital Management LLC lifted its stake in shares of Masimo by 1.5% in the third quarter. Geode Capital Management LLC now owns 792,886 shares of the medical equipment provider's stock valued at $105,741,000 after buying an additional 11,984 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its stake in shares of Masimo by 9.8% in the third quarter. Massachusetts Financial Services Co. MA now owns 792,166 shares of the medical equipment provider's stock valued at $105,619,000 after buying an additional 70,440 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts recently weighed in on MASI shares. Wells Fargo & Company increased their target price on shares of Masimo from $193.00 to $205.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Piper Sandler increased their target price on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Needham & Company LLC restated a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Raymond James raised their price target on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. Finally, Stifel Nicolaus restated a "buy" rating and set a $190.00 price target (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, Masimo presently has a consensus rating of "Moderate Buy" and a consensus price target of $194.80.
Get Our Latest Stock Report on MASI
Insider Buying and Selling
In other Masimo news, COO Bilal Muhsin sold 30,000 shares of the company's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction on Friday, March 14th. The shares were sold at an average price of $166.13, for a total transaction of $341,064.89. Following the sale, the director now owns 16,581 shares of the company's stock, valued at $2,754,601.53. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.
Masimo Price Performance
Shares of NASDAQ:MASI traded up $2.52 during trading on Friday, reaching $168.21. The stock had a trading volume of 472,958 shares, compared to its average volume of 622,472. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88. The business's 50-day moving average price is $174.84 and its 200 day moving average price is $157.65. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock has a market capitalization of $9.07 billion, a PE ratio of 116.01 and a beta of 1.03.
Masimo (NASDAQ:MASI - Get Free Report) last posted its earnings results on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.42 by $0.38. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The company had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. As a group, equities analysts predict that Masimo Co. will post 4.1 earnings per share for the current year.
About Masimo
(
Free Report)
Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.
See Also
Before you consider Masimo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.
While Masimo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
